Response to Dr. Mark Litt's Commentary.

Abstract

We wish to thank Dr. Mark Litt for his very thoughtful and comprehensive commentary (Litt 2019) on our body of work describing the potential use of the World Health Organization (WHO) risk drinking levels (World Health Organization, 2000) for judging success/efficacy in clinical trials generally, but in pharmacotherapy trials in particular. Importantly, Dr. Litt highlights the importance of this work for clinical practice. He rightly describes the issue that many clinicians face, the fact that many treatment-seekers do not desire complete abstinence, both because it is a goal that is difficult to achieve and because many social situations that involve alcohol can be difficult to navigate for non-drinkers. This article is protected by copyright. All rights reserved.